Cancer News, Research & Analysis
Time-sensitive and reliable coverage of pharmaceutical industry
developments, clinical trials, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) or on: +44 (0)20 7769 6707 (London) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €750/£675 a year per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna head office, Austria, European Union: +43 (0)1 71 71 8 900
London office, United Kingdom: +44 (0)20 7769 6707
You have the option of taking a 3 week free trial to Cancer Stat before subscribing.
2. Patients
Patients can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
- 2. MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies
- 3. Study shows which patients with advanced prostate cancer will benefit from chemotherapy
- 4. Israeli company to test if fecal bacteria pills boost cancer immunotherapy
- 5. Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer
- 6. Canadian Candu produces cancer therapy isotope
- 7. Bristol Myers must face $6.4 billion lawsuit over delayed cancer drug
- 8. Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
- 9. Essex boy, cancer survivor, and now Wimbledon wildcard at 26 - meet Ryan Peniston
- 10. Summary of opinion: Pepaxti,melphalan flufenamide, 23/06/2022, Positive
Last updated at 10:22 GMT
Hot News Makers
Health/Pharma Companies
-
58559.90
-
5991.46
-
3584.93
-
2325.89
-
2195.76
-
1839.07
-
1823.49
-
1421.14
-
1202.08
-
1021.52
Last updated at 10:10 GMT